Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented at the American Heart Association's Scientific Sessions.
Lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
- Details
- Category: Novartis
Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (>=65 years of age).
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.
BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting
- Details
- Category: AstraZeneca
AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty,
Sanofi-aventis and Regeneron expand strategic Antibody Collaboration
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
Novartis launches Prevacid® 24 HR over-the-counter
- Details
- Category: Novartis
Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009.
Nycomed reports continued satisfactory performance in the third quarter 2009
- Details
- Category: Nycomed
Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilient after losing patent protection in May in 12 European countries. On a regional basis, sales in most emerging markets exhibited strong growth. The pipeline portfolio advanced significantly.
More Pharma News ...
- Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
- FDA approves GSK's pandemic H1N1 vaccine
- Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement
- WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix⢠Vaccine
- Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
- Novartis to expand its human vaccines presence in China
- New Merck Begins Operations